Kornimate/medical-research-clean huggingface dataset:
approach for optimizing meropenem therapy in intubated and mechanically-ventilated, adult patients with severe gram-negative lower respiratory tract infection

Conditions: Lower Respiratory Tract Infection

Summary: antibacterial drugs are facing increasing limitations in terms of effectiveness due to emergence resistance. improved antibacterial drug monitoring approaches are particularly needed in nosocomial infections occurring in icu patients, including ventilator-associated pneumonia and ventilator-associated tracheobronchitis, where decreased susceptibility of the etiological organisms is observed worldwide and pharmacokinetic alterations frequently observed. no routine drug monitoring is available for betalactams at the point of care in a useful time frame (i.e., within a few hours after having collected the blood specimens). the purpose of this study is to compare mon4strat approach for reaching and maintaining a meropenem pre-determined pk-pd target when compared to conventional meropenem dose.


Eligibility criteria:
inclusion criteria: 1. males and non-pregnant, non-lactating females, 18 years of age or older 2. currently intubated and mechanically-ventilated subjects in the icu 3. suspicion of lower respiratory tract infection 4. presence of gram-negative organism(s) by gram stain or by culture of pre-therapy respiratory specimen (eg, endotracheal aspirate \[eta\], bronchoalveolar lavage \[bal\], or mini-bal) or previous colonization 48 h before screening. 5. initial empiric antimicrobial meropenem regimen 6. at least two risk factors for multidrug-resistant organisms 7. provision of written informed consent by the subject or a family member or a close relative or waiver of consent. exclusion criteria: 1. subjects who have received antibiotic therapy for gram-negative lrt infection for ≥ 36 hours at the time of randomization 2. subjects with known or suspected type 1 hypersensitivity to beta-lactam and/or cephalosporin 3. subjects taking valproic acid for a seizure disorder 4. subjects who have had a left hemisphere stroke within five days and there is an increased risk of fatal brain oedema 5. subjects who have cystic fibrosis, human immunodeficiency virus (hiv) infection with cd4 count \<100 cell/mm3 or invasive fungal infection of the lung 6. neutropenia (anc \< 103 neutrophils/mm3) 7. bone marrow transplant. 8. subjects who have been on mechanical ventilation for \>28 days

Keywords: mon4strat treatment drug monitoring antibiotic resistance beta-lactams resistance meropenem health care-asociated infection
cervical length in cases of placenta previa

Conditions: Placenta Previa

Summary: this study establishes the relationship between cervical length and whether it can be used to predict haemorrhage and preterm delivery in cases of placenta previa.

some studies have reported an association between ultrasonographic decreased cervical length and the likelihood of complications as antepartum or post-partum haemorrhage requiring an emergency caesarean section (cs) . the safety of trans-vaginal scanning is not in doubt, and the technique now has widespread acceptance. as a consequence, the clinical presentation of placenta previa has changed and most low lying placentas are diagnosed during the second trimester anomaly scan. the objective of this study was to establish if there is a relation between transvaginal ultrasonographic measurement of cervical length in cases of placenta previa and whether it can be used as a predictor for antepartum haemorrhage or not.

Eligibility criteria:
inclusion criteria: 1. age: 20-45 years old 2. single pregnancy 3. fetal gestational age 28 to \< 36 weeks 4. normal amniotic fluid index (afi) 5. diagnosis of placenta previa by pelvic ultrasound that was confirmed when the lower placental edge overlies the internal cervical os on transvaginal ultrasound (tvs). exclusion criteria: 1. threatened preterm labor and maternal use of vaginal progesterone. 2. preterm premature rupture of membranes; 3. polyhydramnios; 4. presence of cercelage and history of cervical cone biopsy which both affect cervical length. 5. diagnosis of multiple fetal anomalies; 6. women with other risk factors for intra-partum hemorrhage

Keywords: placenta previa cervical length antepartum haemorrhage
a study of lasmiditan (ly573144) treatment in children aged 6 to 17 with migraine

Conditions: Migraine

Summary: the reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. the study will last up to 20 weeks and may include up to 4 visits.


Eligibility criteria:
inclusion criteria: * participants must have a history of migraine with or without aura as defined by international headache society international classification of headache disorders, 3rd edition (ichd-3) (ichd-3 2018) diagnostic criteria 1.1 or 1.2.1 and meets the following criteria: * history of migraine attacks for more than 6 months * reports at least 2 and no more than 8 moderate-to-severe migraine attacks per month in the 2 months prior to screening visit * duration of a typical untreated migraine attack (excluding sleep) is greater than or equal to 3 hours * participant has not, by history, experienced satisfactory response with a previous migraine therapy, in the opinion of the investigator * participant must be able to swallow a tablet * for participants taking migraine preventive medication, treatment regimen is stable and has been taken for at least 3 months prior to screening * participants must weigh at least 15 kilograms (kg) exclusion criteria: * participants must not be pregnant or nursing * participants must not have any acute, serious, or unstable medical condition * participants must not be actively suicidal or at significant risk for suicide, in the opinion of the investigator

Keywords: acute
mtpr with shockwave on pain & function of shs in stroke

Conditions: Stroke

Summary: background: shoulder-hand syndrome is considered a significant reason for the reduction of upper limb functions after stroke. purpose: to investigate the influence of myofascial trigger points (mtrps) release and shockwave therapy on pain and functions of the upper extremity in stroke patients with diabetic neuropathy.

methods: two equal groups of thirty stroke patients, divided into, study group: which treated with mtrps release combined with shockwave therapy and conventional program, while control group: treated with a conventional selected exercise program.

Eligibility criteria:
inclusion criteria: * stroke from 4:8 months * age ranging from 45:60 years * all the patients were identified with shs as diagnosed by the diagnostic criteria for shs post-stroke 18 and were in stage i of syndrome evolution exclusion criteria: * any other causes of shoulder pain in the hemiplegic side of the body * a cognitive impairment * structured joint deformity in the painful shoulder or hand * other musculoskeletal disorders of ue.

Keywords: stroke diabetic neuropathy shoulder hand syndrome
quantitative d-dimer level and anticoagulant therapy in idiopathic intracranial hypertension

Conditions: Idiopathic Intracranial Hypertension

Summary: idiopathic intracranial hypertension (iih) is a syndrome characterized by elevated intracranial pressure (icp) of unknown etiology. the investigators aim to study the quantitative d-dimer level and the role of anticoagulant therapy in the absence of occlusive sinus thrombosis in iih patients.

24 patients with iih according to the modified dandy criteria were enrolled. headache impact test (hit6), ophthalmological assessment including frisen classification for papilledema, visual acuity, visual field by perimetry, and visual evoked potentials were performed to the patients. serum quantitative d-dimer level was measured using the enzyme-linked immunosorbent assay (elisa) technique for the patients and for 24 healthy matched controls. patients were divided into two groups: group (a) received acetazolamide and low molecular weight heparin (lmwh) in a prophylactic dose for 2 weeks while group (b) received acetazolamide only. both groups continued the acetazolamide 1-2g/day for 6 months. the investigators followed-up the patients after one and six months later through the hit6 test and the ophthalmological assessment.

Eligibility criteria:
inclusion criteria: * iih patients of both sexes fulfilling the modified dandy criteria exclusion criteria: * disturbed conscious level, focal neurological signs, seizures, cerebral venous sinus thrombosis or stenosis, deep venous thrombosis or pulmonary embolism, malignancy, and acute nephritic syndrome. * patients with signs of disseminated intravascular coagulopathy and septic sinus thrombosis * patients with a history of cerebral granuloma or infection, cerebrovascular stroke, head trauma or surgery. * pregnant females or those who terminated their pregnancy in the last four weeks were also excluded.

Keywords: iih d-dimer microthrombi anticoagulation
a single-dose study to evaluate the pharmacokinetics, safety, and tolerability of bms-986263 in participants with varying degrees of liver impairment

Conditions: Hepatic Impairment

Summary: the primary purpose of this study is to evaluate the effect of liver impairment on the safety and pharmacokinetics (pk) of bms-986263


Eligibility criteria:
for more information regarding bristol-myers squibb clinical trial participation, please visit www.bmsstudyconnect.com. inclusion criteria: * bmi ≥ 18 kg/m\^2 and weight ≥ 50 kg at screening (bmi = weight \[kg\]/height \[m\^2\]). * participants with normal hepatic function as judged by the investigator * participants with hepatic impairment as judged by the investigator exclusion criteria: * clinically relevant abnormal medical history, abnormal findings on physical examination, vital signs, ecg, or laboratory tests at screening that the investigator judges as likely to interfere with the objectives of the trial or the safety of the participant. * any major surgery within 4 weeks of study drug administration * previous exposure to bms-986263 other protocol-defined inclusion/exclusion criteria apply.
moxibustion as an adjuvant for benign prostatic hyperplasia with lower urinary tract symptoms: a pilot study

Conditions: BPH; Benign Prostatic Hyperplasia; Benign Prostatic Hypertrophy; Lower Urinary Tract Symptom

Summary: this study aims to explore the feasibility of moxibustion as a supplementary intervention and to assess the sample size for verifying the effectiveness and safety of integrative treatment involving moxibustion compared with conventional treatment for patients with benign prostate hyperplasia (bph) accompanying moderate to severe lower urinary tract symptoms (luts).

patients who diagnosed as bph with moderate to severe luts aged 20 to 80 years old will be divided into two groups, one is moxibustion plus conventional therapy group and the other is conventional therapy group. patients who belong to moxibustion plus conventional therapy group will be treated moxibustion for eight times by a korean medicine doctor with conventional therapy by a urologist. patients who belong to conventional therapy group will be treated with conventional therapy only, and they can receive moxibustion therapy after the clinical trial is finished. ipss, post void residual volume (pvr) and peak urine flow (qmax) will be checked to evaluate the effectiveness and safety.

Eligibility criteria:
inclusion criteria: 1. male patients aged 20-80 years diagnosed with bph with a prostate size over 20 gm 2. greater than or equal to eight score on ipss 3. submit written consent 4. who can understand and answer ipss. exclusion criteria: 1. prostate or bladder malignancy 2. received herbal medication for lower urinary tract symptoms within 1 week 3. history of brain disease could cause urinary difficulty 4. having problems on answering ipss due to cognitive impairment. 5. signs of acute urinary tract infection 6. diabetic mellitus 7. neurogenic bladder

Keywords: moxibustion
the effect of tai chi exercise among elders with sarcopenia

Conditions: Sarcopenia in Elderly; Tai Chi

Summary: sarcopenia has been defined as a disease which presented as low muscles strength, low muscle quantity or quality and low physical activity. the prevalence of sarcopenia is increasing with the age and it is also included in one of geriatric syndromes. several criteria have been mentioned for diagnosis of sarcopenia, such as european working group on sarcopenia in older people (ewgsop)、foundation for the national institutes of health biomarkers consortium sarcopenia project (fnih) and asian working group for sarcopenia (awgs). in european, the prevalence rate of sarcopenia is 9.25-18%; 5-7% canadian and 14.4% taiwanese elders have been diagnosed as sarcopenia, respectively. the sarcopenia has been found its relationship with adverse outcomes of fall down, fracture, disability, and death. the cytokines and decline in anabolic hormones play a role in the pathogenesis of sarcopenia. tai chi exercise is one of qigong and well-popular in chinese population, and is helpful to integration of body movements. tai chi exercise is less complicated and emphasized people's awareness of self-care which presented the relationship between human and nature. tai chi exercise could improve muscle performance, balance and have the benefit for fall down prevention in the elders and patients with frailty. furthermore, tai chi has been found that it also could improve the muscle power and power strength in sarcopenic elders by team training. furthermore, immune makers of inflammation process have been noted their diminishments by qigong intervention. the aim of this study is to investigate the effect of tai chi exercise in sarcopenic elders through practicing at home. the differences of muscles strength, muscle quantity or quality and physical activity after interventions would be recorded and analyzed. the cytokines related to the sarcopenia process would also be sampled.


Eligibility criteria:
inclusion criteria: * age 60 or older; * with a diagnosis of sarcopenia \[defined as ewgsop-2\] (6); * without planned exercise program or unplanned admission in 6 months; * could tolerate tests of muscle power and strength. exclusion criteria: * uncontrolled diabetes mellitus; * uncontrolled cardiovascular diseases; * uncontrolled hypertension; * knee or hip prosthesis, pacemaker, fracture in the previous 6 months, * critical cognitive (mmse\<23) * mini nutritional assessment (mna \<17) * physical dysfunctions that could not tolerate our tests
a phase ii trial testing oral administration of lucitanib in patients with fibroblast growth factor receptor (fgfr)1-amplified or non-amplified estrogen receptor positive metastatic breast cancer

Conditions: Breast Cancer

Summary: the aim of the study is to evaluate the objective response rate (orr) of single agent lucitanib in metastatic breast cancer patients with fgfr1-amplified, fgfr1-non amplified with 11q amplification, or fgfr1-non amplified without 11q amplification.


Eligibility criteria:
inclusion criteria: * histologically confirmed breast adenocarcinoma. * presence of an accessible metastatic lesion for biopsy or at least one archived metastatic tumour sample. * prior first-line systemic therapy in the metastatic setting. * demonstrated progression of disease by radiological or clinical assessment. * female patient, aged ≥18 years old. * estimated life expectancy \>3 months. * normal left ventricular function * adequate haematological, hepatic and renal functions. * for women with childbearing potential, a negative pregnancy test prior to initiation of the study drug and willingness to use an effective contraception. * ability to swallow oral capsules or tablets. exclusion criteria: * more than two lines of chemotherapy with or without targeted therapy in the metastatic setting. * previous treatment with bevacizumab within 3 months of first dose of investigational medicinal product. * active central nervous system metastases, cerebral oedema, and/or progressive growth. * patients with impaired cardiac function. * uncontrolled arterial hypertension * patients with history of thrombotic disorders or hereditary risk factors of thromboembolic events * serum potassium level below lower limit of normal * uncontrolled hypothyroidism. * pregnant or breastfeeding women.
angioplasty of distal lesions for carriers of inoperable post-embolic htp

Conditions: Pulmonary Hypertension

Summary: currently, the standard treatment for proximal thromboses lesions responsible for post-embolic pulmonary hypertension, is the surgical thromboendarterectomy. when the ravages are judged too distal or the patient is judged inoperable for a curative surgical gesture, there is no evidence of any therapeutic option, exept for k anti-vitamins for recurrent embolism. prognosis is then pejorative with a 60% mortality at 5 years. this study propose an alternative treatment for these patients in therapeutic "dead end". this is about applying arterial thrombosis technique to the pulmonary circulation.


Eligibility criteria:
inclusion criteria: * patients over 18 years * patients with a pulmonary hypertension diagnosed by right catheterisation, with a mean arterial pressure \>30 mmhg and arterial pulmonary resistance \> 3 uw. * patients with group 4 (dana point) pulmonary hypertension, thromboembolic. * chronic thrombosis visible to scanner, pulmonary irm angiogram or to pulmonary angiogram. * patient's file refused by the reference center multidisciplinary coordination meetings for surgical thromboendartériectomy or refusal from the patient to be operate. * absence of counter-argument to the femoral venous or jugular way. * normal kidney function or moderatly degraded (clearance\>30 ml) or dialysed renal failure * persons affiliated to national social security * signed free consent by patients exclusion criteria: * pulmonary hypertension pos-embolic operated by thromboendarteriectomy * pulmonary hypertension group 1 of dana point, meaning idiopathic, familial, post-anorectics, associate with a congenital heart disease associated to a scleroderma, associated to a chronic hemolytic disease * pulmonary hypertension group 2 of dana point, associated with a left cardiovascular disease * pulmonary hypertension group 3 of dana point, associated to a respiratory disease * pulmonary hypertension group 5 of dana point, of unclear or multifactorial mechanism * hypersensitivity to hexabrix, to iodinated contrast product or one of its components * obvious thyrotoxicosis * protected major persons * pregnant or breastfeeding women * persons deprived of liberty * persons in emergency situations. * no consent signed or approoved * persons no affiliated to national social security

Keywords: distal lesions post-embolic htp angioplasty
a blind, randomized and controlled study of live attenuated varicella vaccines

Conditions: Varicella

Summary: the purpose of this study is to evaluate the protective effect, safety and immunogenicity of a live attenuated varicella vaccine in healthy children.

this study is a randomized, blind, controlled phase iii clinical trial. the purpose of this study is to evaluate the protective effect, safety and immunogenicity of a live attenuated varicella vaccine manufactured by sinovac (dalian) vaccine technology co., ltd. the control is diluent of lyophilized vaccine manufactured by sinovac (dalian) vaccine technology co., ltd. all participants are healthy, and will be randomly assigned into experimental group or control group in the ratio 1:1.

Eligibility criteria:
inclusion criteria: * healthy volunteer between 1 - 12 years old; * proven legal identity; * guardian(s) of the volunteer and/or volunteers themselves should be capable of understanding the written consent form, and such form should be signed before the volunteer being included into this study; exclusion criteria: * prior vaccination with varicella vaccine or with history of varicella zoster virus (vzv) infection; * axillaty temperature \> 37.0 °c; * history of allergy to any vaccine or vaccine ingredient, or serious adverse reaction(s) to vaccination, such as urticaria, difficulty in breathing, angioneurotic edema, abdominal pain, etc; * history of epilepsy, seizures or convulsions, or a family history of mental illness, autoimmune disease or immunodeficiency; * severe malnutrition, congenital malformation, developmental disorders, or serious chronic diseases; * acute disease or acute stage of chronic disease within 7 days prior to study entry; * receipt of any of the following products: 1. any subunit vaccine or inactivated vaccine within 7 days prior to study entry; 2. any live attenuated vaccine within 1 month prior to study entry; 3. any blood product, immunosuppressant, hormone, or other investigational medicine(s) within 30 days prior to study entry; * any significant abnormity of heart, lung, skin, or pharynx; * any other factor that suggesting the volunteer is unsuitable for this study based on the opinions of investigators;

Keywords: live attenuated varicella vaccine protective effect safety immunogenicity child
infectivity of norovirus in shellfish treated with high hydrostatic pressure processing-human challenge study

Conditions: Healthy

Summary: norwalk virus and related "norwalk-like viruses" are the most common cause of outbreaks of stomach sickness (nausea, vomiting, diarrhea) in older children and adults in the united states. these viruses are sometimes found in drinking water, ice, shellfish and in other foods. they can be spread easily from contact with water, food, objects or hands that have even small amounts of feces from someone who was sick. the purpose of this research study is to the effectiveness of high hydrostatic pressures processing (hpp) treatment on norovirus infected shellfish. norwalk virus can survive in shellfish and still be able to cause sickness. hpp inactivates microorganisms living both on the surface and on the interior of the food. the goal of the study is to determine whether hpp treatment on oysters spiked with norovirus will reduce infection rates in people consuming raw infected oysters.


Eligibility criteria:
inclusion criteria: * normal healthy volunteer * age must be between 18 and 50 years of age exclusion criteria: * have a job in which you handle food * are a health care worker with direct patient contact * work in a child care, elderly care center or if you live with young children or anyone who has a weak immune system * are not willing or able to wash your hands every time after you go to the bathroom, or before and after you prepare or handle food throughout the whole study * are anemic * are not willing to give us permission to store and use your data and samples

Keywords: norovirus gastroenteritis clinical trial stomach flu oysters shellfish high hydrostatic pressures